Replies to post #91315 on Cytodyn Inc (CYDY)

[Scooter McCabe]

H.C. Wainwright analyst Yi Chen downgraded CytoDyn to Neutral from Buy without a price target. The company's "rising valuation" appears principally driven by enthusiasm for leronlimab as a potential treatment for COVID-19 treatment but "myriad uncertainties remain," Chen tells investors in a research note. The analyst estimates that leronlimab as a COVID-19 treatment is now valued by the market at roughly $2.6B. The risk/reward ratio for CytoDyn "has worsened palpably," says Chen.

Read more at:
https://thefly.com/landingPageNews.php?id=3120723

This is what I call lazy analysis. If the investors in this company were solely here for COVID the stock would have crashed below 1 dollar on the 30th.

"Myriad of uncertanties" did not seem to be a problem when HC Wainright recommended this as a buy. There were no results for COVID when the buy recommendation came out. Nothing has materially changed in the science. The EINDs are still 80% efficacy.

The only thing that occurred was the dip on the 30th. Whoever looked at this simply said to themselves "penny stock" and did no further due diligence . No mention of HIV BLA, no mention of NASH, no mention of the cancer basket trial.

So I have to take this with a grain of salt and stick with my own DD.